Cancer Network

Cancer Network, along with the peer-reviewed journal ONCOLOGY, offers healthcare professionals valuable insights and expert opinions on topics related to cancer. This includes information on screening, early detection, diagnosis, treatment options, and prevention strategies for various types of cancer.

International

English

Journal, Online/Digital

Outlet metrics

Domain Authority

Ranking

Global

#343294

United States

#116496

Health/Health

#2376

Traffic sources

Monthly visitors

Articles

Telisotuzumab Vedotin Earns FDA Accelerated Approval in c-MET+ NSCLC

1 day ago | cancernetwork.com | Russ Conroy

The FDA has granted accelerated approval to telisotuzumab vedotin-tllv (Emrelis) as a treatment for adults with locally advanced or metastatic nonsquamous non–small cell lung cancer (NSCLC) and high c-MET protein expression previously managed wih systemic therapy, according to a press release from the developer, AbbVie.1With this decision, telisotuzumab vedotin is the first and only available therapy for this NSCLC subtype.
Phase 2B Trial for Cancer Vaccine in Newly Diagnosed Glioblastoma Will Continue

3 days ago | cancernetwork.com | Russ Conroy

Based on an interim analysis of trial data, the phase 2b SURVIVE study (NCT05163080) assessing SurVaxM, a cancer vaccine, in patients with newly diagnosed glioblastoma will continue, according to a press release from Roswell Park Comprehensive Cancer Center.1Findings from the recently completed interim futility analysis and ongoing assessment by an independent data safety monitoring board indicated that the SURVIVE trial could continue as planned without any protocol changes.
Breastfeeding Support May Reduce TNBC Incidence, Mitigate Disparities

5 days ago | cancernetwork.com | Russ Conroy

Better support for breastfeeding may help avoid new cases of triple-negative breast cancer (TNBC) in patients who are White or Black, according to findings from a pooled analysis study published in NPJ Breast Cancer.1Breastfeeding for less than 6 months conferred higher odds of TNBC for those who were White (pooled odds ratio [pOR], 1.41; 95% CI, 1.15-1.74; I2 = 67%) or Black (pOR, 1.35; 95% CI, 1.06-1.73; I2 = 0%).
Fruquintinib Combo Shows Early Activity in RAS/BRAF+ Metastatic CRC

6 days ago | cancernetwork.com | Courtney Flaherty

Early clinical activity and tolerability were reported in a small cohort of patients with RAS/BRAF wild-type metastatic colorectal cancer (mCRC) who received fruquintinib (Fruzaqla) in combination with capecitabine (Xeloda), according to data from a phase 1/2 study (NCT05016869) presented at the 2025 American Association for Cancer Research Annual Meeting.
Revumenib Yields Meaningful Benefit in NPM1-Mutated Acute Myeloid Leukemia

6 days ago | cancernetwork.com | Russ Conroy

Treatment with revumenib produced clinically meaningful responses in an older population of patients with heavily pretreated relapsed/refractory acute myeloid leukemia (AML) harboring NPM1 mutations, according to findings from the phase 2 portion of the phase 1/2 AUGMENT-101 study (NCT04065399) published in Blood.1Among 64 evaluable adult patients, a complete response (CR) or CR with partial hematologic recovery (CRh) occurred in 23.4% (95% CI, 13.8%-35.7%; 1-sided P = .0014).
Chemoradiation Shows Responses Across Dose Levels in Anal Cancer

6 days ago | cancernetwork.com | Russ Conroy

Intensity-modulated radiotherapy (IMRT) demonstrated favorable 6-month complete clinical responses administered at a standard or reduced dose among patients with early-stage anal cancer, according to findings from the phase 2 PLATO-ACT4 trial (ISRCTN88455282) published in Lancet Oncology.1 At 6 months, a complete clinical response occurred in 84.4% (n = 135/160) of all evaluable patients, with respective rates of 84% (n = 46/55; 95% CI, 71.2%-92.2%) and 85% (n = 89/105; 95% CI, 76.4%-91.0%)...
Frontline Efti Combo Yields Meaningful Survival in PD-L1-Low HNSCC

1 week ago | cancernetwork.com | Russ Conroy

Combining eftilagimod alfa (efti) with pembrolizumab (Keytruda) demonstrated an overall survival (OS) benefit in the first-line treatment of a small cohort of patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) harboring a PD-L1 combined positive score (CPS) of less than 1, according to a press release on cohort B findings from the phase 2b TACTI-003/KEYNOTE-C34 trial (NCT04811027) .1 With a data cutoff date of March 31, 2025, the median OS among 31 evaluable...
Cemsidomide Combo May Produce Responses in Multiple Myeloma

1 week ago | cancernetwork.com | Russ Conroy

Treatment with cemsidomide (CFT7455) plus dexamethasone elicited responses across multiple doses in a small cohort of patients with multiple myeloma, according to a press release on findings from the phase 1/2 CFT7455-1101 study (NCT04756726) from the drug’s developer, C4 Therapeutics, Inc.1With a data cutoff date of April 30, 2025, cemsidomide at a dose of 100 µg once daily produced an overall response rate of 50% among 10 evaluable patients.
FDA Lifts Clinical Hold on Tabelecleucel in EBV+ Lymphoproliferative Disease

1 week ago | cancernetwork.com | Russ Conroy

The FDA has lifted its clinical hold on the investigational new drug applications for tabelecleucel (tab-cel; Ebvallo) as a treatment for those with Epstein-Barr Virus (EBV)–positive post-transplant lymphoproliferative disease (PTLD), according to a news release from the developer, Atara Biotherapeutics, Inc.1 The FDA originally placed a clinical hold on the program for tab-cel in January 2025 due to Good Manufacturing Practice (GMP) compliance issues associated with a pre-license inspection...
Neurovascular Sparing during Radiation Reduces Incidence of ED in Prostate Cancer

1 week ago | cancernetwork.com | Tim Cortese

The 1.5T Elekta Unity MR-linear accelerator (Linac) was able to reduce the amount of radiation exposed to key structures responsible for erection in patients with prostate cancer, according to a press release from the developer, Elekta.1 The incidence of erectile dysfunction (ED) at 6 months was 6% with the Elekta Unity MR-Linac and neurovascular sparing and 21% with the same dosage without neurovascular sparing (P = .015); at 12 months, it was 8.5% vs 38%, respectively (P <.001); and at 18...